5GV.F GENOVIS AB SE-40

Healthcare Biotechnology Frankfurt Exchange
2.11 EUR
Close of Nov 11, 2026
1.41 2.15
Market cap
EUR 143M
P/E
70.5x
P/B
5.17x
ROE
3.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 5GV.F undervalued?

Graham number

The Graham number of GENOVIS AB SE-40 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GENOVIS AB SE-40 fundamental analysis

No fundamental analysis for GENOVIS AB SE-40 yet.

GENOVIS AB SE-40 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GENOVIS AB SE-40

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a c…

Full company profile